Who funds cancer immunotherapy research?

We count 201 funded cancer immunotherapy projects, active between 2019 and 2034, from 6 funders. The most came from EU · ERC (88 projects), EU · MSCA (39 projects) and Wellcome (17 projects). The median award is $2.1M, across the 199 of 201 projects that list an amount.

Funded projects

201

Funders

6

Median award

$2.1M

Open calls now

0

Top funders of cancer immunotherapy research

Projects whose title or summary mentions cancer immunotherapy. Median award: of the projects that list an amount, in US dollars; “—” when fewer than 3 do.

Open cancer immunotherapy funding calls

No open call mentions cancer immunotherapy in our listings today. We add new calls twice a day; create a free account to get an alert when one opens.

Forecast: announced, not open yet

1 forecast call on cancer immunotherapy. Funders publish forecasts before a call opens; you can't apply to these yet, and dates can change.

• ForecastCanine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
  National Institutes of HealthNot specifiedExpected to open November 25, 2026

Funded cancer immunotherapy projects

A sample, latest start first, at most three per program.

• Human gamma delta T cells: from fundamental biology to cancer immunotherapy
  Wellcome · £3,290,610 · ends 2034
• From cells and synapses to connectivity and cure in paediatric autoimmune encephalitis
  Wellcome · £3,447,090 · ends 2033
• Dynamic changes at the immune synapse controlling CTL function
  Wellcome · £3,500,000 · ends 2033
• CAREER: Structure-Aware Protein Language Models for Decoding Immune Recognition
  NSF · CISE · $522,190 · ends 2031
• Unravelling the Immune Mechanisms of Oral Tolerance to Find a Cure for Food Allergy
  UKRI · MRC · £2,542,244 · ends 2030
• Natural killer cells subvert immune checkpoint therapy of tumors
  NIH · NCI · $3,182,665 · ends 2029
• CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against T cell non-Hodgkin lymphoma (NHL): a first-in-human phase I clinical trial
  FDA · Food and Drug Administration · $3,421,591 · ends 2029
• Role of the Retrosplenial Cortex in the Progression of AD Pathogenesis in Mouse and Human
  NIH · NIA · $3,221,450 · ends 2029
• Cell-based Immunotherapy Products
  NIH · NCI · $13,633,885 · ends 2029
• Controllable solid tumor immunotherapy based on a wireless thermos-activator
  NIH · NCI · $3,036,844 · ends 2029

How we count

Funded projects come from public award records (NIH RePORTER, NSF, EU CORDIS, UKRI Gateway to Research, Wellcome, the Gates Foundation, DOE, NASA and USDA NIFA) whose title or summary matches “immunotherapy or checkpoint inhibitor or checkpoint inhibitors”. NIH lists each budget year separately; one project counts once. Amounts are as the funder lists them; medians use only projects that list one, in US dollars. Open calls and forecasts are from our listings of October 28, 2026. A project can mention a topic without being mainly about it, so treat the counts as a guide to who funds the area.